top of page

BREAKING NEWS: 

AEYE-DS is the first ever FDA-cleared AI technology to autonomously diagnose diabetic retinopathy (DR) using a portable retinal camera

 1-minute AI diabetic eye exam ​at any point of care

The only FDA-cleared solution providing instant AI diagnosis using handheld or tabletop cameras

See it in action

AEYE Diagnostic Screening

AEYE-DS utilizes Artificial Intelligence (AI) technology to instantly diagnose diabetic retinopathy from retinal images

Artboard 4 copy_15x.png
Website and pith deck images (22).png

AEYE with AURORA

AEYE-DS software in use on a computer presenting the fundus images analyzed with the diabetic retinopathy diagnostic result

First to be cleared with both a desktop camera and a portable handheld camera

Topcon NW fundus camera with the AEYE System - AEYE with Topcon NW-400

AEYE with TOPCON

Artboard 4 copy_15x_edited.png
See the AEYE-DS
with Topcon in Action
See the AEYE-DS
with Aurora in Action

Best-in-class Accuracy

Group 6356499 (1).png

The only solution to be proven accurate in clinical trials on both desktop and handheld cameras

Desktop

91%

Specificity

93%

Sensitivity

Handheld

89%-94%

Specificity

92%-93% 

Sensitivity

Vector icon of an eye with a target representing accuracy

1-minute Screening

The only AI that requires only 1 image per eye, and rarely requires dilation

1 min

exam avg.

Instant

Diagnostic report

>99%

Imageability

Vector Art of a Feemale healthcare professional with a reimbursable report representing closing care gaps

Closes Care Gaps

Enables point-of-care screening instead of referring to a specialist

CPT 92229

Reimbursement Code

Measure 117

HEDIS Quality Measure

Over 40M

people with diabetes in the US and 500M worldwide are at risk of sight-threatening diabetic retinopathy.

85%

of people over 40 with diabetes will develop diabetic retinopathy.

Why it matters

Screening Prevents Blindness

Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.

new map copy.PNG
Only 15% to 50%

of patients with diabetes in the US adhere to the recommended screening.

Closing care gaps

Replacing specialist screening with AI diagnosis

Using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap

Before

After

The first image shows the current diabetic retinopathy screening process where by a patient receives an annual referral for an eye exam and less than 50% adhere to the screening. In the second image the solution is shown where by a patient receives on-the-spot diagnosis during a GP visit and is then either cleared for 12 months due to negative result or referred to a specialist for treatment if the result is positive.
Vector Art of Point of Care Screening Solution Process by AEYE Health. The image has Male Doctor photo detecting diabetic reinopathy and screening tool

Benefits of Point-of-Care Screening

vector art of reimbursable report

Reimbursable

 Dedicated CPT code 92229 for AI diabetic retinopathy screening

Vector Art of AEYE Health Care - An image has two vector hands catching the heart representing closes care gaps

Closes Care Gaps

Closes the care diabetic eye gap, improving HEDIS scores and and Star ratings

Advantages of AEYE-DS

Group 6356498.png

Accessible

Enables point of care screenings anywhere,  whether at home or in-clinic

Vector Art of hand is positioned beneath the eye vector icon symbolizing care and support and representing practical

1-minute Screening

Requires only one image per eye; rarely requires dilation;  producing instant diagnosis

See what people are saying about us

Sean Ianchulev MD, MPH, CEO at Eyenovia. Professor of Ophthalmology at UCSF & Mt. Sinai Smiling Photo

The time has finally come for autonomous screening technology to exceed the efficacy of the human expert. The implications are that it can be practical for deployment on the front lines of population health – the primary care offices, where over 99% imageability and single image diagnostic acquisition are tantamount to market success

Sean Ianchulev

MD, MPH, CEO at Eyenovia. Professor of Ophthalmology at UCSF & Mt. Sinai

Frame 6356052.png

Our Research

Autonomous comprehensive diagnostic screening for a broad range of diseases using retinal images

Autonomous Diagnostic Screening Specialist | AEYE Health

Explore how you can implement sight-saving diagnostic screening

Thanks for submitting!

bottom of page